Skip to main content

Replimune Group Inc (REPL) Stock

Replimune Group Inc Stock Details, Movements and Public Alerts

Stock Details

Replimune Group Inc (REPL), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $15.39. Over the past 52 weeks, it has ranged between $1.50 and $15.67. This places the current price at 98.2% of its 52-week high and 926.0% above its 52-week low. Recent trading volume was recorded at 1,679,296. The 14-day Relative Strength Index (RSI) stands at 69.24, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $10.38 by 48.27%. Similarly, it is above its 200-day moving average of $8.08 by 90.47%. The MACD histogram is 0.59, indicating bullish momentum (MACD Line: 1.09, Signal Line: 0.50). There is currently 1 active alert set for REPL by users.

52-Week Range

$15.67 - $1.50

-1.79% from high · +926.00% from low

Avg Daily Volume

8,226,724

20-day average

100-day avg: 6,922,143

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

6.91

EV/EBITDA

-0.24

EPS (TTM)

-$3.38

Beta

0.90

Less volatile than market

Q:How is REPL valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is REPL's risk profile compared to the market?
With a beta of 0.90, Replimune Group Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.91 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-312,555,008

Return on Equity

-107.90%

Return on Assets

-45.00%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is REPL's business model?
Profitability metrics are not available for this stock.
Q:What are REPL's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$1.1B

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

83.94M

Book Value/Share

$2.01

Asset Type

Common Stock

Q:What is REPL's market capitalization and position?
Replimune Group Inc has a market capitalization of $1.1B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 83.94M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does REPL's price compare to its book value?
Replimune Group Inc's book value per share is $2.01, while the current stock price is $15.39, resulting in a price-to-book (P/B) ratio of 7.66. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$19.33

25.60% upside potential

Analyst Recommendations

Strong Buy

2

Buy

2

Hold

3

Sell

1

Strong Sell

0

Q:How reliable are analyst predictions for REPL?
8 analysts cover REPL with 50% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $19.33 implies 25.6% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on REPL?
Current analyst recommendations:2 Strong Buy, 2 Buy, 3 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 13, 2026, 02:26 AM

Technical Indicators

RSI (14-day)

69.24

Neutral

50-Day Moving Average

$10.38

48.27% above MA-50

200-Day Moving Average

$8.08

90.47% above MA-200

MACD Line

1.09

MACD Signal

0.50

MACD Histogram

0.59

Bullish

Q:What does REPL's RSI value tell investors?
The RSI (Relative Strength Index) for REPL is currently 69.24, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret REPL's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.09 above the signal line at 0.50, with histogram at 0.59. This bullish crossover suggests upward momentum is building. The 50-day MA ($10.38) is above the 200-day MA ($8.08), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 13, 2026, 12:46 AM

Active Alerts

Alert Condition
Reaches new 52-week low
Threshold
N/A
Created
May 13, 2026, 07:13 AM

Stay Ahead of the Market with Replimune Group Inc Alerts

Set up price alerts for Replimune Group Inc and get notified instantly when the price hits your target. Never miss an important price movement again.